Inari Medical (NASDAQ:NARI) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical (NASDAQ:NARI) in a report published on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $68.00 price objective on the stock.

A number of other research analysts have also commented on the company. Piper Sandler lowered their price target on Inari Medical from $55.00 to $50.00 and set a neutral rating for the company in a research report on Wednesday, May 1st. Robert W. Baird lowered their price target on Inari Medical from $65.00 to $63.00 and set an outperform rating for the company in a research report on Wednesday, July 31st. William Blair assumed coverage on Inari Medical in a research report on Thursday, July 25th. They issued an outperform rating for the company. Truist Financial reissued a hold rating and issued a $55.00 target price (down previously from $60.00) on shares of Inari Medical in a research report on Wednesday, July 31st. Finally, Needham & Company LLC reissued a hold rating on shares of Inari Medical in a research report on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $61.29.

Inari Medical Price Performance

NARI traded down $0.07 during midday trading on Friday, reaching $48.65. 609,748 shares of the company’s stock traded hands, compared to its average volume of 1,047,042. The firm has a fifty day moving average of $49.87 and a two-hundred day moving average of $48.26. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -118.66 and a beta of 1.01. Inari Medical has a 52 week low of $36.73 and a 52 week high of $71.85.

Insider Buying and Selling

In related news, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $46.60, for a total value of $1,864,000.00. Following the sale, the director now owns 925,359 shares in the company, valued at approximately $43,121,729.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Rebecca Chambers sold 964 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $45.39, for a total value of $43,755.96. Following the sale, the director now owns 9,944 shares in the company, valued at approximately $451,358.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $46.60, for a total value of $1,864,000.00. Following the completion of the sale, the director now owns 925,359 shares in the company, valued at approximately $43,121,729.40. The disclosure for this sale can be found here. Insiders have sold 222,744 shares of company stock worth $11,494,500 in the last 90 days. Insiders own 10.60% of the company’s stock.

Institutional Trading of Inari Medical

Several institutional investors have recently added to or reduced their stakes in NARI. Vanguard Group Inc. boosted its stake in Inari Medical by 11.1% during the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after purchasing an additional 561,562 shares during the last quarter. Norges Bank purchased a new stake in Inari Medical during the 4th quarter valued at $29,491,000. Brown Advisory Inc. boosted its stake in Inari Medical by 17.6% during the 4th quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company’s stock valued at $110,501,000 after purchasing an additional 255,182 shares during the last quarter. First Light Asset Management LLC bought a new position in shares of Inari Medical during the 1st quarter valued at $10,265,000. Finally, American Century Companies Inc. lifted its holdings in shares of Inari Medical by 26.8% during the 2nd quarter. American Century Companies Inc. now owns 980,917 shares of the company’s stock valued at $47,231,000 after buying an additional 207,485 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.